Journal
NATURE COMMUNICATIONS
Volume 6, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms8002
Keywords
-
Categories
Funding
- European Community [602901]
- Associazione Italiana per la Ricerca sul Cancro (AIRC) IG grant [12812, 12944]
- AIRC MFAG [11349]
- MIUR-Fondazione Piemontese per la Ricerca sul Cancro-ONLUS
- AIRC [9970]
- FPRC Ministero della Salute
- Ministero dell'Istruzione, dell'Universita e della Ricerca, progetto PRIN
- Universita di Torino [ORTO11RKTW]
- Fondazione Oncologia Niguarda Ca' Granda Onlus
Ask authors/readers for more resources
The development of molecularly targeted anticancer agents relies on large panels of tumour-specific preclinical models closely recapitulating the molecular heterogeneity observed in patients. Here we describe the mutational and gene expression analyses of 151 colorectal cancer (CRC) cell lines. We find that the whole spectrum of CRC molecular and transcriptional subtypes, previously defined in patients, is represented in this cell line compendium. Transcriptional outlier analysis identifies RAS/BRAF wild-type cells, resistant to EGFR blockade, functionally and pharmacologically addicted to kinase genes including ALK, FGFR2, NTRK1/2 and RET. The same genes are present as expression outliers in CRC patient samples. Genomic rearrangements (translocations) involving the ALK and NTRK1 genes are associated with the overexpression of the corresponding proteins in CRC specimens. The approach described here can be used to pinpoint CRCs with exquisite dependencies to individual kinases for which clinically approved drugs are already available.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available